SORRENTO THERAPEUTICS (SRNE) Covered Calls

SORRENTO THERAPEUTICS covered calls Sorrento Therapeutics Inc is a biopharmaceutical company. It is engaged in the discovery, acquisition, development and commercialization of proprietary drug therapeutics for addressing unmet medical needs in the United States.

You can sell covered calls on SORRENTO THERAPEUTICS to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for SRNE (prices last updated Thu 4:16 PM ET):

SORRENTO THERAPEUTICS (SRNE) Stock Quote
Last Change Bid Ask Volume P/E Market Cap
3.60 +0.31 3.50 3.60 1.3M - 0.4B
Covered Calls For SORRENTO THERAPEUTICS (SRNE)
Expiration Strike Call Bid Net Debit Return
If Flat
Annualized
Return If Flat
Dec 21 2.5 1.05 2.55 -2.0% -19.7%
Mar 15 2.5 1.30 2.30 8.7% 26.2%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial


Extended Business Description

Sorrento Therapeutics, Inc. is a biopharmaceutical company, which engaged in the acquisition, discovery, development and commercialization of proprietary drug therapeutics that address significant unmet medical needs. Its products and technologies have much broader clinical applications including cancer, autoimmune disorders, metabolic and infectious diseases. Sorrento's clinical pipeline includes Cynviloq which is entering a registrational bio-equivalent study versus albumin-bound paclitaxel and Resiniferatoxin, which is in a Phase 1/2 study at the NIH to treat terminal cancer patients suffering from intractable pain. In addition, Sorrento has one of the industry's most diverse fully human antibody libraries (G-MAB) and novel toxins/proprietary conjugation chemistries allowing Sorrento to generate antibody-drug conjugates (ADCs). The Sorrento ADCs have well-defined drug antibody ratios (DAR) in contrast to approved ADCs, which are heterogeneous mixtures with different DARs. These differentiating characteristics may lead to the development of a new of generation ADCs with improved stability and pharmacokinetics while reducing off-target effects. Sorrento Therapeutics was founded by Henry Ji, in 2006 and is headquartered in San Diego, CA.